Markus K. A. Herrmann
University of Göttingen
16 Papers
250 Citations
Markus K. A. Herrmann is an academic researcher from University of Göttingen. The author has contributed to research in topics: Chemoradiotherapy & Proctitis. The author has an hindex of 13, co-authored 16 publications.
Chat about Author
Papers
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Jochen Gaedcke,Marian Grade,Klaus Jung,Markus D. Schirmer,Peter Jo,Christoph Obermeyer,Hendrik A. Wolff,Markus K. A. Herrmann,Tim Beissbarth,Heinz Becker,Thomas Ried,Michael Ghadimi +11 more
TL;DR: The first to report the mutation status of KRAS and BRAF in pre-therapeutic biopsies from locally advanced rectal cancers emphasizes the importance to expand current mutation analyses, whereas BRAF mutations are not relevant for rectal carcinogenesis.
99
Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
Hendrik A. Wolff,Tobias Overbeck,Ralph M.W. Roedel,Robert Michael Hermann,Markus K. A. Herrmann,Tereza Kertesz,Hilke Vorwerk,Andrea Hille,Christoph Matthias,Clemens F. Hess,Hans Christiansen +10 more
TL;DR: Chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity and should be evaluated in future clinical trials.
Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy
Leif Hendrik Dröge,Hanne Elisabeth Weber,Manuel Guhlich,Martin Leu,Lena-Christin Conradi,Jochen Gaedcke,Steffen Hennies,Markus K. A. Herrmann,Margret Rave-Fränk,Hendrik A. Wolff +9 more
TL;DR: VMAT treatment in preoperative CRT for LARC showed the potential to substantially reduce high-grade acute and late toxicity and it is concluded that the reduced toxicity after VMAT irradiation may pave the way for more efficient systemic therapies, and hopefully improved patient survival in the multimodal treatment of LARC.
A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment
Andrea Hille,Emine Schmidt-Giese,Robert Michael Hermann,Markus K. A. Herrmann,Margret Rave-Fränk,Markus D. Schirmer,Hans Christiansen,Clemens F. Hess,Giuliano Ramadori +8 more
TL;DR: Calprotectin and lactoferrin faecal values changed during radiation treatment and after cessation of radiation, with correlation to acute proctitis symptoms in most of the patients, including patients with any grade of toxicity.
27
High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma.
Hendrik A. Wolff,Ismene Raus,Klaus Jung,P. Schüler,Markus K. A. Herrmann,Steffen Hennies,Hilke Vorwerk,Andrea Hille,Clemens F. Hess,Hans Christiansen +9 more
TL;DR: The data indicate that normal tissue and tumor tissue may behave similarly with respect to treatment response, since high-grade acute organ toxicity during radiochemotherapy showed itself to be an independent prognostic marker in the patient population.
27